Couldn't agree less Rayda.
You should answer your own question to Gilman: "how do you think the market was going to respond .... particularly when there was a snowballs chance it ever would given that in so many patients the cancer had already spread to other organs"?
Maybe he thought the market would respond sanely - ie, place little importance on the failure to achieve its primary end point, due to its near-irrelevance to how SIR-Spheres were being used. Maybe he thought they'd get to the second line which confirmed SIR-Spheres efficacy in controlling liver tumors.
The Company is obliged to present facts - that is actually an "informed release". Its up to shareholders to understand what they are reading.
If you were an informed shareholder the events of last March presented an opportunity of a lifetime (and I'm certainly not including myself in that category, otherwise I would have been smart enough to double-down, rather than watching on like a stunned mullet).
Can't tell you how many sugar-coated announcements I've read from companies marching into administration.
Carry on Gilman.
Add to My Watchlist
What is My Watchlist?